MétaCan
Menu
← Back to cohort

Asthma control and QoL among Canadian patients with severe eosinophilic asthma (SEA): 2-year real-world results

2025· article· W4416637319 on OpenAlexaffabout
Erika Penz, Mackenzie A. Hamilton, Brett Lancaster, Charles St. Pierre, Jason Lee, Delbert Dorscheid, Pierre-Alexandre Ménard, Tharwat Fera, Amin Thawer, Brandie Walker, Gordon L. Sussman, Warren Ramesh, Olga Tourin, Irfan Ullah Khan, George Philteos, Lawrence Mbuagbaw

Bibliographic record

Venuenot available
Typearticle
Language
FieldMedicine
TopicAsthma and respiratory diseases
Canadian institutionsVanguard CollegeUniversity of TorontoUniversity of CalgaryCentre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-QuébecMedical Council of CanadaSt. Joseph’s Healthcare HamiltonCanadian Sleep & Circadian NetworkUniversity of British ColumbiaToronto Public HealthUniversity of AlbertaUniversity of Saskatchewan
Fundersnot available
KeywordsBenralizumabAsthmaQuality of life (healthcare)Observational studyConcomitant

Abstract

fetched live from OpenAlex

Introduction Evaluation of benralizumab use in adults with SEA found early and sustained asthma control and improved QoL in the Canadian POWER study at 6 months (CJRCCSM 2024;8(3):99-107). Long-term benralizumab data on asthma control and QoL are lacking in these patients. Aims and Objectives To assess SEA control and QoL outcomes in patients with uncontrolled SEA treated with benralizumab up to 2 years in a Canadian real-world setting Methods POWER ( NCT03833141 ) is a real-world, prospective, single-arm observational study of patients with uncontrolled SEA treated with benralizumab. Patients were recruited from 20 Canadian clinics from 2019–2022. Inclusion criteria were blood eosinophils ≥300 cells/µL, Asthma Control Questionnaire (ACQ-6) score ≥1.5, and benralizumab naïve. Change in ACQ-6 was measured up to 2 years after initiating benralizumab (minimum clinically important difference: change of 0.5 points). QoL was assessed with the standardized Asthma QoL Questionnaire (AQLQ(S)+12). Results Of 141 patients assessed at baseline, 56 were followed to week 104. Mean (95% CI) change in ACQ-6 at week 104 from baseline was -1.64 (-1.99, -1.28 [baseline: 3.26; week 104: 1.47]); 83.9% of patients achieved clinically meaningful improvement at week 104 from baseline. At week 104, 28.6% and 28.6% of patients were well and partially controlled. AQLQ(S)+12 mean (SD) total score improved from 3.15 (1.02) at baseline (n=130) to 5.14 (1.15) at week 104 (n=50); 92.0% of patients had clinically meaningful QoL improvement (ΔAQLQ(S)+12≥0.5). Conclusions Patients with SEA experienced continued clinically meaningful improvement in asthma control and QoL up to 2 years after initiating benralizumab.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.107
Threshold uncertainty score0.216

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.003
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.002
Science and technology studies0.0010.001
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.004
GPT teacher head0.218
Teacher spread0.214 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes2
Has abstractyes

Explore more

Same topicAsthma and respiratory diseases→French-language works237,207→